Home Cart Sign in  
Chemical Structure| 330161-87-0 Chemical Structure| 330161-87-0

Structure of SU6656
CAS No.: 330161-87-0

Chemical Structure| 330161-87-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SU6656 is an inhibitor of Src family kinases with IC50 values of 280, 20, 130, and 170 nM for Src, Yes, Lyn, and Fyn, respectively. It inhibits FAK phosphorylation at Y576/577, Y925, and Y861 sites, as well as p-AKT.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SU6656

CAS No. :330161-87-0
Formula : C19H21N3O3S
M.W : 371.45
SMILES Code : O=S(C1=CC2=C(NC(/C2=C\C(N3)=CC4=C3CCCC4)=O)C=C1)(N(C)C)=O
MDL No. :MFCD10565928
InChI Key :LOGJQOUIVKBFGH-YBEGLDIGSA-N
Pubchem ID :5312137

Safety of SU6656

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of SU6656

RTK
PI3K-AKT
cytoskeleton

Isoform Comparison

Biological Activity

Target
  • Fyn

    Fyn, IC50:170 nM

  • Src

    Src, IC50:280 nM

  • Yes

    YES, IC50:20 nM

  • Lyn

    Lyn, IC50:130 nM

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.69mL

0.54mL

0.27mL

13.46mL

2.69mL

1.35mL

26.92mL

5.38mL

2.69mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

[1]McCarthy SD, Jung D, et al. c-Src and Pyk2 protein tyrosine kinases play protective roles in early HIV-1 infection of CD4+ T-cell lines. J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):118-26.

[2]Blake RA, Broome MA, et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol. 2000 Dec;20(23):9018-27.

[3]Iwona Cicha,et al. Dual inhibition of Src family kinases and Aurora kinases by SU6656 modulates CTGF (connective tissue growth factor) expression in an ERK-dependent manner. Int J Biochem Cell Biol. 2014 Jan;46:39-48.

[4] S H Kim,et al. Inhibition of p21 and Akt potentiates SU6656-induced caspase-independent cell death in FRO anaplastic thyroid carcinoma cells. Horm Metab Res. 2013 Jun;45(6):408-14.

[5]Nathalie Dussault,et al. Human B lymphocytes and non-Hodgkin's lymphoma cells become polyploid in response to the protein kinase inhibitor SU6656. Blood Cells Mol Dis. Jul-Aug 2007;39(1):130-4.

[6]Cyril Thouverey,et al. Selective inhibition of Src family kinases by SU6656 increases bone mass by uncoupling bone formation from resorption in mice. Bone. 2018 Aug;113:95-104.

[7]Michelle A Hardyman,et al. TNF-α-mediated bronchial barrier disruption and regulation by src-family kinase activation. J Allergy Clin Immunol.2013 Sep;132(3):665-675.e8.

[8]Kumar A, et al. Pharmacological investigations on possible role of Src kinases in neuroprotective mechanism of ischemic postconditioning in mice. Int J Neurosci. 2014 Oct;124(10):777-86.

 

Historical Records

Categories